Esben A. Carlsen

Copenhagen, 2100, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Assessment of data-driven gating for cardiac motion extraction and LVEF estimation from routine [18F]FDG LAFOV PET.

Assessment of data-driven gating for cardiac motion extraction and LVEF estimation from routine [18F]FDG LAFOV PET.

Journal: Physics in medicine and biology

Published: September 04, 2026

First-in-Human: Simultaneous Hyperpolarized 1- 13 C-Pyruvate Magnetic Resonance Spectroscopy and 18 F-FDG PET (hyperPET) Imaging of a Patient With Lymphoma.

First-in-Human: Simultaneous Hyperpolarized 1- 13 C-Pyruvate Magnetic Resonance Spectroscopy and 18 F-FDG PET (hyperPET) Imaging of a Patient With Lymphoma.

Journal: Clinical nuclear medicine

Published: November 12, 2024

Prospective phase II trial of [68Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy.

Prospective phase II trial of [68Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy.

Journal: EJNMMI research

Published: June 21, 2024

Routine Use of [64Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans.

Routine Use of [64Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 13, 2024

Phase II study of uPAR-PET/CT for staging of primary breast cancer in comparison with ultrasound and fine needle biopsies.

Phase II study of uPAR-PET/CT for staging of primary breast cancer in comparison with ultrasound and fine needle biopsies.

Journal: Scientific reports

Published: February 06, 2024

Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial.

Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial.

Journal: Diagnostics (Basel, Switzerland)

Published: September 07, 2023

An Investigation of Lesion Detection Accuracy for Artificial Intelligence-Based Denoising of Low-Dose 64Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms.

An Investigation of Lesion Detection Accuracy for Artificial Intelligence-Based Denoising of Low-Dose 64Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: August 24, 2022

Prospective Phase II Trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT Imaging of Integrin αvβ3 for Prognostication in Patients with Neuroendocrine Neoplasms.

Prospective Phase II Trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT Imaging of Integrin αvβ3 for Prognostication in Patients with Neuroendocrine Neoplasms.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 20, 2022

First-in-Human Study of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET for Integrin αvβ3 Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability.

First-in-Human Study of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET for Integrin αvβ3 Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability.

Journal: Diagnostics (Basel, Switzerland)

Published: March 14, 2022

First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using 18F-labeled Active-Site Inhibited Factor VII (18F-ASIS): Potential as Companion Diagnostic.

First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using 18F-labeled Active-Site Inhibited Factor VII (18F-ASIS): Potential as Companion Diagnostic.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 04, 2022

A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms.

A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms.

Journal: EJNMMI research

Published: February 18, 2022

Activity Dose Reduction in 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability.

Activity Dose Reduction in 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability.

Journal: Molecular imaging and biology

Published: October 06, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026